Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer

Phase 1

Completed

Conditions: Advanced Solid Tumors
Non Small Cell Lung Cancer

Interventions: Drug: sunitinib
Drug: docetaxel

First Posted Date: 2008-07-10

Last Posted Date: 2008-11-11

Lead Sponsor: Pfizer

Target Recruit Count: 49

Registration Number: NCT00712504

Locations: 🇺🇸
Pfizer Investigational Site, Madison, Wisconsin, United States

Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings

Completed

Conditions: Psoriasis

Interventions: Drug: etanercept (Enbrel®)

First Posted Date: 2008-07-02

Last Posted Date: 2015-07-27

Lead Sponsor: Pfizer

Target Recruit Count: 926

Registration Number: NCT00708708

Locations: 🇩🇪
Westfaelische Wilhelms-Universitaet Muenster, Zentr. f. Derm, Muenster, NRW, Germany

Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia

Phase 2

Terminated

Conditions: Pneumonia, Bacterial

Interventions: Drug: tigecycline
Drug: imipenem/cilastatin

First Posted Date: 2008-06-30

Last Posted Date: 2012-07-10

Lead Sponsor: Pfizer

Target Recruit Count: 108

Registration Number: NCT00707239

Locations: 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan

Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial

Phase 3

Completed

Conditions: Gaucher Disease

Interventions: Drug: Taliglucerase alfa

First Posted Date: 2008-06-27

Last Posted Date: 2018-10-04

Lead Sponsor: Pfizer

Target Recruit Count: 45

Registration Number: NCT00705939

Locations: 🇨🇱
Pontificia Universidad Catolica de Chile, Santiago, Chile
🇦🇺
Bone Marrow Transplant Service, The Royal Melbourne Hospital, Parkville, Victoria, Australia
🇺🇸
Department of Human Genetics, Emory University School of Medicine, Decatur, Georgia, United States

and more 8 locations

Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma

Phase 4

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Sunitinib Malate (SU011248)

First Posted Date: 2008-06-27

Last Posted Date: 2013-01-18

Lead Sponsor: Pfizer

Target Recruit Count: 105

Registration Number: NCT00706706

Locations: 🇨🇳
Pfizer Investigational Site, Xi'an, China

A Study of PF-04217903 in Patients With Advanced Cancer

Phase 1

Terminated

Conditions: Neoplasms

Interventions: Drug: PF-04217903

First Posted Date: 2008-06-27

Last Posted Date: 2012-06-25

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT00706355

Locations: 🇺🇸
Pfizer Investigational Site, Detroit, Michigan, United States

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

Phase 1

Completed

Conditions: Non-Alcoholic Steatohepatitis(NASH)

Interventions: Drug: Active treatment
Drug: Placebo

First Posted Date: 2008-06-27

Last Posted Date: 2009-08-13

Lead Sponsor: Pfizer

Target Recruit Count: 9

Registration Number: NCT00706537

Locations: 🇺🇸
Pfizer Investigational Site, Durham, North Carolina, United States

Nonrestorative Sleep RSQ (Restorative Sleep Questionnaire) Development-- Methodology Study

Terminated

Conditions: Nonrestorative Sleep

Interventions: Procedure: PSG

First Posted Date: 2008-06-26

Last Posted Date: 2019-03-04

Lead Sponsor: Pfizer

Target Recruit Count: 64

Registration Number: NCT00705601

Locations: 🇨🇦
Pfizer Investigational Site, Toronto, Ontario, Canada

Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]

Completed

Conditions: Lymphoma, Mantle-Cell
Carcinoma, Renal Cell, Advanced
Gastrointestinal Stroma Tumors

Interventions: Drug: Sunitinib
Drug: Temsirolimus
Drug: Axitinib

First Posted Date: 2008-06-18

Last Posted Date: 2022-12-05

Lead Sponsor: Pfizer

Target Recruit Count: 1520

Registration Number: NCT00700258

Locations: 🇩🇪
Office of Detlef Muller, Bautzen, Germany
🇩🇪
Klotz, Weiden, Germany
🇩🇪
Carsten Lange, Bernburg, Germany

and more 74 locations

Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer

Phase 3

Terminated

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: sorafenib
Drug: sunitinib malate

First Posted Date: 2008-06-18

Last Posted Date: 2013-01-14

Lead Sponsor: Pfizer

Target Recruit Count: 1075

Registration Number: NCT00699374

Locations: 🇬🇧
Pfizer Investigational Site, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy